Stay updated on Pembrolizumab in Early NK/T-cell Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Early NK/T-cell Lymphoma Clinical Trial page.

Latest updates to the Pembrolizumab in Early NK/T-cell Lymphoma Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedAdded a consolidated Locations section listing sites in California, New Jersey, New York, and Texas. Removed the prior state-specific location headings for California, New Jersey, New York, and Texas (Revision: v3.3.3).SummaryDifference0.6%

- Check22 days agoNo Change Detected
- Check29 days agoNo Change Detected
- Check43 days agoChange DetectedThe page now displays a revised version label: Revision: v3.3.2, replacing the previous v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check50 days agoChange DetectedRemoved the funding-lapse notice that warned information on the page may not be up to date and directed users to opm.gov for status updates.SummaryDifference0.4%

- Check64 days agoChange DetectedNo additions or deletions were detected on the page; the study details and sections remain unchanged.SummaryDifference0.5%

- Check71 days agoChange DetectedResults for Pembrolizumab in untreated ENKTL have been posted, including the Complete Response Rate with related dates. The Study Protocol and Statistical Analysis Plan PDF is now available under Study Documents.SummaryDifference1%

- Check86 days agoChange DetectedCore content updated to show that results are now submitted/available instead of none being posted.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Early NK/T-cell Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Early NK/T-cell Lymphoma Clinical Trial page.